Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — Q4 2021 Earnings Presentation
14 slides from Heartbeam's earnings presentation, Mar 24, 2022
Slide 1: Heart Attack Detection
Heart Attack Detection Fourth Quarter and Full Year 2021 Financial Results Conference Call NASDAQ: BEAT March 24, 2022
Slide 2: Disclaimers
Fourth Quarter 2021 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial positio
Slide 3: Agenda
Fourth Quarter 2021 Financial Results Conference Call Agenda • Introduction, Recent Announcements and Market Opportunity Branislav Vajdic • Product Timelines and Updates, and Partnerships Jon Hunt • Model at Scale and Financial Results Rick Brounstein • Closing Summary Branislav Vajdic 30 years of e
Slide 4: Key Fourth Quarter, Full Year 2021 and Subsequent Highlights
Fourth Quarter 2021 Financial Results Conference Call Key Fourth Quarter, Full Year 2021 and Subsequent Highlights • Successful IPO on the Nasdaq Capital Market under the ticker symbol “BEAT” on November 11, 2021 • Appointed as Chief Operating Officer Alan Baumel, a 30 year product development, manu
Slide 5: HeartBeam Solutions True Platform Technology
Fourth Quarter 2021 Financial Results Conference Call HEARTBEAM SOLUTIONS TRUE PLATFORM TECHNOLOGY ED solution for more ED accurate MI detection Software Q3 2022 Complete telehealth solution for remote MI monitoring Telehealth Q1 2023 5
Slide 6: HeartBeam US Market Opportunity
Fourth Quarter 2021 Financial Results Conference Call HeartBeam US Market Opportunity 6x Bigger Than AFIB Market ~18M* ~8M ~3M AFib Patients Prior MI Patients Total CAD Patients $2 billion $4+ billion $10+ billion 1. National Hospital Ambulatory Medical Care Survey: 2016 Emergency Department Summary
Slide 7: Telehealth Market
Fourth Quarter 2021 Financial Results Conference Call Telehealth Market U.S Telehealth Market ($ in Billions) • Adoption rate of telehealth increased $636 dramatically during COVID-19, especially in cardiology, radiology, behavioral health, and online consultation 32% CAGR • Governments actively dev
Slide 8: ER Software Tool Updates
Fourth Quarter 2021 Financial Results Conference Call ER Software Tool Updates • Partnered with LIVMOR Inc., a digital health solutions company, to build a HeartBeam branded version of LIVMOR’s Halo+ FDA cleared turnkey solution for remote patient monitoring (“RPM”) to connect physicians and patient
Slide 9: Telehealth Updates
Fourth Quarter 2021 Financial Results Conference Call Telehealth Updates • Partnered with Triple Ring Technologies to co-develop its telehealth complete solution 3D vector Electrocardiogram (ECG) collection device for remote heart attack (MI) monitoring Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 202
Slide 10: Market Landscape: Substantial Capabilities Beyond Existing Offerings
Fourth Quarter 2021 Financial Results Conference Call Market Landscape Substantial Capabilities Beyond Existing Offerings Heart Attack Detection 12L ECG Capable Integrates history & symptoms Uses Baseline Long Term Use Potential AFib Detection AFlutter Detection 10
Slide 11: Sample Financial Model for our ED & Telehealth Solutions at Scale
Fourth Quarter 2021 Financial Results Conference Call Sample Financial Model for our ED & Telehealth Solutions at Scale Revenue at TAM Penetration % Sample Financial Model $25M Sample Financial Model $100M ED Telehealth Total ED Telehealth Total Telehealth Total Revenue 12,500,000 12,500,000 25,000,
Slide 12: FY 2021 Financial Highlights
Fourth Quarter 2021 Financial Results Conference Call FY 2021 Financial Highlights $ in Thousands Years ended December 31, 2021 2020 Operating Expenses: General & Administrative $2,030 $655 Research & Development 255 133 Total Operating Expenses (2,285) 788 Loss from Operations (2,285) (788) Interes
Slide 13: Closing Summary
Fourth Quarter 2021 Financial Results Conference Call Closing Summary • Well known and previously unsolved problem with a massive worldwide market • Product timeline and milestones on track for FDA Clearance and market launch • Initiated strategic partnerships to advance Emergency Department (ED) My
Slide 14: Q&A
Q&A Company Investor Relations Rick Brounstein Chris Tyson Chief Financial Officer Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050